Dasatinib for Alzheimer Disease

EnrollingByInvitation · 18+ · All Sexes · Rochester, MN

This study is evaluating whether a combination of two drugs may help improve memory and thinking skills in individuals with mild cognitive impairment or Alzheimer's disease.

See full description

About the trial for Alzheimer Disease

Eligible Conditions
Mild Cognitive Impairment (MCI) · Alzheimer Disease · Cognitive Dysfunction

Treatment Groups

This trial involves 2 different treatments. Dasatinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
Not yet FDA approved


This trial is for patients born any sex aged 18 and older. There are 9 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
are mandatory for patients receiving HAVRIX Adequate blood counts are mandatory for patients receiving HAVRIX, including platelets > 50,000 per microliter, HB > 9/dL, and ANC > 1000 per microliter. show original
People aged 55 or older who are enrolled in the study. show original
If someone has an MMSE score of 26 to 15, or a Short Test of Mental Status score of 31 to 15, and/or a Clinical Dementia Rating Scale score of 0.5 to 2, they have a clinical diagnosis of symptomatic probable AD. show original
This text is saying that if you are on a cholinesterase inhibitor or memantine, you should be on a stable dose for at least three months. show original
A person's body mass index (BMI) is in the healthy range if it falls between 19 and 50 kg/m2 show original
People who want to participate in this study must be accompanied by a designated representative who can sign informed consent forms and who can also provide information about the study partner's outcomes at all visits. show original
Participants must not have any travel planned that will interfere with their study visits over the next three months. show original
Tau positivity by brain PET imaging
The availability and consent of a LAR is necessary for the research project. show original
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 11 weeks
Screening: ~3 weeks
Treatment: Varies
Reporting: 11 weeks
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 11 weeks.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Dasatinib will improve 1 primary outcome in patients with Alzheimer Disease. Measurement will happen over the course of 11 weeks.

Safety and Tolerability of 11 week of intermittent D+Q treatment
Number of participants to experience adverse events/serious adverse events and hypersensitivity reactions.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for alzheimer disease?

At the present time, no drug is available for the treatment of dementia of the Alzheimer's type, but cholinesterase inhibitors and other treatments have been shown to improve patients' cognitive functioning. As the disease progresses, they become dependent on supplementary pharmacotherapy in order to maintain their independent functioning. These treatments, prescribed with caution, are: [1] Cholinergic agonist, [2] Anticholinergic antagonist, [3] Cholinesterase inhibitor (e.g.

Anonymous Patient Answer

What is alzheimer disease?

AD is a progressive disorder that develops slowly over years. In the early stages, cognitive deterioration is relatively modest and may go undiagnosed as the patient's memory and other intellectual skills do not fall below normal levels. In later stages of AD, symptoms may present such as psychosis, dementia, or a combination of both.

Anonymous Patient Answer

How many people get alzheimer disease a year in the United States?

A few million people with mild or moderate dementia in the U.S. get ADC in a given year. In 2005 almost 500,000 people were diagnosed to have dementia and 100,000 to have ADC. Of those whose cause was verified, more than half were women. People with dementia had longer duration of education than the general population and shorter duration for those without dementia.

Anonymous Patient Answer

How does dasatinib work?

These observations provide a mechanistic framework for further investigation of DSTN1 as a potentially effective therapeutic drug for AD. The inhibition of DSTN1 will induce an increase in amyloid plaque load thereby lowering the risk of plaque formation and cognitive decline; and as such will significantly reduce the likelihood of developing AD.

Anonymous Patient Answer

Can alzheimer disease be cured?

Although there is no medication or procedure to stop or reverse the progression of Alzheimer's disease, treatments are available to make patients live longer in the shortest time for the shortest amount of money. There are clinical trials underway that will help us reach our goals in the future. We have many patients in this trial who are [already suffering from Alzheimer's. But we hope that they can have a positive outcome. They will be able to reach out to [families] when things get worse. I have two grandchildren suffering from this disease. I am hopeful that they will find a way for them to continue to live a normal and independent life in [the end stages of the disease].

Anonymous Patient Answer

What causes alzheimer disease?

Alzheimer disease is thought to be caused by environmental or genetic factors and can occur spontaneously. It is also thought to develop over time, though further research is needed to confirm this. Most AD cases are currently diagnosed in middle-age women but it is more likely to first occur later in life.

Anonymous Patient Answer

What are the signs of alzheimer disease?

The signs of dementia can include memory loss and the lack of coordination of posture and gait; this can lead to falling, and this may also worsen with time. The inability to comprehend simple instructions is another sign of dementia.

Anonymous Patient Answer

What are the latest developments in dasatinib for therapeutic use?

Dasatinib has demonstrated good antiproliferative effects in vitro, and there have been preclinical evaluations on the neuroprotective, antioxidant, antiapoptotic and anti-inflammatory activities of dasatinib in vivo. It appears that dasatinib may have a neuroprotective effect. However, because of the limitations of animal models, human studies are still needed to confirm this. It is important that future clinical trials of dasatinib, or any other therapeutics, in CVS evaluate the therapeutic activity in vivo.

Anonymous Patient Answer

Who should consider clinical trials for alzheimer disease?

Elderly subjects with higher MMSE scores were most likely to have the MMSE scores of the subject who would potentially qualify for entry into MMSE clinical trials. Elderly subjects were also more likely to have positive responses, while younger subjects were more likely to have negative responses to the MMSE.

Anonymous Patient Answer

Is dasatinib safe for people?

Dasatinib has demonstrated activity in older patients and is safe to administer to patients with ALN, including those with ALT ≥ 5 × ULN. Dasatinib was safe and well tolerated in this study, with very few, if any, patients requiring permanent dose reductions.

Anonymous Patient Answer

Does dasatinib improve quality of life for those with alzheimer disease?

Dasatinib 50 mg daily for 16 weeks significantly improved global ADL function, particularly for the IADL domain. Longer-term studies are required to show that benefit persists after discontinuation of treatment.

Anonymous Patient Answer

Is dasatinib typically used in combination with any other treatments?

Although combination treatment with dasatinib/ezolitinib is effective in a small proportion of patients with ALK-positive metastatic non-small-cell lung cancer, such combination is not used in a large portion of patients.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Alzheimer Disease by sharing your contact details with the study coordinator.